9月7日康方生物依沃西单抗(AK112)首个全球多中心Ⅲ期临床研究HARMONi的更新数据在世界肺癌大会上公布。该研究评

智通财经
Sep 07
9月7日康方生物依沃西单抗(AK112)首个全球多中心Ⅲ期临床研究HARMONi的更新数据在世界肺癌大会上公布。该研究评估了经三代EGFR-TKI治疗后疾病进展的患者接受依沃西单抗联合化疗方案的疗效与安全性。结果显示中位随访时间达13.7个月OS(总生存期)数据明显改善北美人群的生存获益数据突出。依沃西单抗是全球首个PD-1/VEGF双抗药物。去年依沃西单抗在单药一线治疗PD-L1阳性非小细胞肺癌的国内注册性Ⅲ期临床研究(HARMONi-2)中其PFS(无进展生存期)比默沙东的PD-1帕博利珠单抗(俗称“K药”)长显示出取代K药的潜力。依沃西单抗“一战成名”成为全球最热门的双抗。(每日经济新闻)。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10